These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1046 related articles for article (PubMed ID: 24722494)
1. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Häring HU; Merker L; Seewaldt-Becker E; Weimer M; Meinicke T; Broedl UC; Woerle HJ; Diabetes Care; 2014 Jun; 37(6):1650-9. PubMed ID: 24722494 [TBL] [Abstract][Full Text] [Related]
2. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus. Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC; Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864 [TBL] [Abstract][Full Text] [Related]
3. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial. Søfteland E; Meier JJ; Vangen B; Toorawa R; Maldonado-Lutomirsky M; Broedl UC Diabetes Care; 2017 Feb; 40(2):201-209. PubMed ID: 27913576 [TBL] [Abstract][Full Text] [Related]
4. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Häring HU; Merker L; Seewaldt-Becker E; Weimer M; Meinicke T; Woerle HJ; Broedl UC; Diabetes Care; 2013 Nov; 36(11):3396-404. PubMed ID: 23963895 [TBL] [Abstract][Full Text] [Related]
5. Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials. Tinahones FJ; Gallwitz B; Nordaby M; Götz S; Maldonado-Lutomirsky M; Woerle HJ; Broedl UC Diabetes Obes Metab; 2017 Feb; 19(2):266-274. PubMed ID: 27762093 [TBL] [Abstract][Full Text] [Related]
6. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Rosenstock J; Jelaska A; Frappin G; Salsali A; Kim G; Woerle HJ; Broedl UC; Diabetes Care; 2014 Jul; 37(7):1815-23. PubMed ID: 24929430 [TBL] [Abstract][Full Text] [Related]
7. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC; Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415 [TBL] [Abstract][Full Text] [Related]
8. Empagliflozin as add-on to metformin in people with Type 2 diabetes. Merker L; Häring HU; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC; Diabet Med; 2015 Dec; 32(12):1555-67. PubMed ID: 26031566 [TBL] [Abstract][Full Text] [Related]
9. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC; Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456 [TBL] [Abstract][Full Text] [Related]
10. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Haering HU; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC; Diabetes Res Clin Pract; 2015 Oct; 110(1):82-90. PubMed ID: 26324220 [TBL] [Abstract][Full Text] [Related]
11. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. DeFronzo RA; Lewin A; Patel S; Liu D; Kaste R; Woerle HJ; Broedl UC Diabetes Care; 2015 Mar; 38(3):384-93. PubMed ID: 25583754 [TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Ferrannini E; Berk A; Hantel S; Pinnetti S; Hach T; Woerle HJ; Broedl UC Diabetes Care; 2013 Dec; 36(12):4015-21. PubMed ID: 24186878 [TBL] [Abstract][Full Text] [Related]
13. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Rosenstock J; Jelaska A; Zeller C; Kim G; Broedl UC; Woerle HJ; Diabetes Obes Metab; 2015 Oct; 17(10):936-48. PubMed ID: 26040302 [TBL] [Abstract][Full Text] [Related]
14. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Ferrannini E; Seman L; Seewaldt-Becker E; Hantel S; Pinnetti S; Woerle HJ Diabetes Obes Metab; 2013 Aug; 15(8):721-8. PubMed ID: 23398530 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Rosenstock J; Seman LJ; Jelaska A; Hantel S; Pinnetti S; Hach T; Woerle HJ Diabetes Obes Metab; 2013 Dec; 15(12):1154-60. PubMed ID: 23906374 [TBL] [Abstract][Full Text] [Related]
16. Empagliflozin in combination with oral agents in young and overweight/obese Type 2 diabetes mellitus patients: A pooled analysis of three randomized trials. Romera I; Gomis R; Crowe S; de Pablos-Velasco P; Aranda U; García A; Kis SG; Naderali E J Diabetes Complications; 2016; 30(8):1571-1576. PubMed ID: 27499456 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of dapagliflozin add-on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Jeong IK; Choi KM; Han KA; Kim KA; Kim IJ; Han SJ; Lee WY; Yoo SJ Diabetes Obes Metab; 2024 Nov; 26(11):5065-5077. PubMed ID: 39223856 [TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Roden M; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC; Cardiovasc Diabetol; 2015 Dec; 14():154. PubMed ID: 26701110 [TBL] [Abstract][Full Text] [Related]
19. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea. Shin Y; Moon JH; Chin HJ; Ferrannini E; Lim S Endocrinol Metab (Seoul); 2020 Jun; 35(2):329-338. PubMed ID: 32615717 [TBL] [Abstract][Full Text] [Related]
20. Comparison Of Efficacy And Safety Profile Of Empagliflozin As A Combination Therapy In Obese Type 2 Diabetic Patients. Babar M; Hussain M; Ahmad M; Akhtar L J Ayub Med Coll Abbottabad; 2021; 33(2):188-191. PubMed ID: 34137526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]